Rating Change
BMO Capital reiterated its Outperform rating on LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX) on August 12, 2026.
reiterateNASDAQ:LBRX
BMO Capital Reiterates Outperform Rating on LB Pharmaceuticals Inc Common Stock (LBRX)
BMO Capital reiterated its Outperform rating on LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX) on August 12, 2026.
At publication ·
What changed
LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX) · reiterate
- Firm
- BMO Capital
- Rating
- Outperform to Outperform
- Price at event
- $45.38
- Market capitalization
- $508.8M
At a glance
Key takeaways
- BMO Capital reiterated an Outperform rating on LB Pharmaceuticals (LBRX) on August 12, 2026, with the stock trading at $45.38 and a market capitalization of $508.8 million.
Market Context
LB Pharmaceuticals Inc Common Stock operates in the Healthcare sector. The stock currently trades at $45.38 with a market capitalization of $508.8M.
Analyst coverage from BMO Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for LB Pharmaceuticals Inc Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for LB Pharmaceuticals Inc Common Stock
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 12, 2026 | BMO Capital | Outperform | N/A |
| Aug 03, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 21, 2026 | BMO Capital | Outperform | N/A |
| Jul 07, 2026 | Wolfe Research | Outperform | N/A |
| Apr 27, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View LBRX Stock Page
Frequently Asked Questions
What does the Outperform rating mean for LBRX?
A rating of Outperform from BMO Capital reflects the analyst's outlook on LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LBRX forecast page.